Business Description
Editas Medicine Inc
NAICS : 325412
SIC : 2834
ISIN : US28106W1036
Description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.89 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | -0.17 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -6.6 | |||||
| Beneish M-Score | -2.93 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -12.8 | |||||
| 3-Year EBITDA Growth Rate | 1.3 | |||||
| 3-Year EPS without NRI Growth Rate | -0.7 | |||||
| 3-Year FCF Growth Rate | 17.3 | |||||
| 3-Year Book Growth Rate | -12.1 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -40.47 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.42 | |||||
| 9-Day RSI | 34.09 | |||||
| 14-Day RSI | 33.83 | |||||
| 3-1 Month Momentum % | -12.7 | |||||
| 6-1 Month Momentum % | -39.23 | |||||
| 12-1 Month Momentum % | -66.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.75 | |||||
| Quick Ratio | 3.75 | |||||
| Cash Ratio | 3.66 | |||||
| Days Sales Outstanding | 15.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.3 | |||||
| Shareholder Yield % | 0.72 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -370.03 | |||||
| Net Margin % | -340.96 | |||||
| FCF Margin % | -309.85 | |||||
| ROE % | -74.59 | |||||
| ROA % | -48.82 | |||||
| ROIC % | -147.84 | |||||
| 3-Year ROIIC % | -1010.92 | |||||
| ROC (Joel Greenblatt) % | -483.83 | |||||
| ROCE % | -62.73 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.78 | |||||
| PB Ratio | 0.93 | |||||
| Price-to-Tangible-Book | 0.93 | |||||
| EV-to-EBIT | 0.23 | |||||
| EV-to-Forward-EBIT | -2.09 | |||||
| EV-to-EBITDA | 0.24 | |||||
| EV-to-Forward-EBITDA | -2.12 | |||||
| EV-to-Revenue | -0.86 | |||||
| EV-to-Forward-Revenue | 0.1 | |||||
| EV-to-FCF | 0.28 | |||||
| Price-to-GF-Value | 0.14 | |||||
| Price-to-Net-Current-Asset-Value | 1.32 | |||||
| Price-to-Net-Cash | 1.38 | |||||
| Earnings Yield (Greenblatt) % | 434.78 | |||||
| FCF Yield % | -116.49 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EDIT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Editas Medicine Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 61.758 | ||
| EPS (TTM) ($) | -2.56 | ||
| Beta | 1.88 | ||
| 3-Year Sharpe Ratio | -0.93 | ||
| 3-Year Sortino Ratio | -1.23 | ||
| Volatility % | 76.23 | ||
| 14-Day RSI | 33.83 | ||
| 14-Day ATR ($) | 0.180906 | ||
| 20-Day SMA ($) | 2.2705 | ||
| 12-1 Month Momentum % | -66.7 | ||
| 52-Week Range ($) | 1.89 - 11.58 | ||
| Shares Outstanding (Mil) | 82.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Editas Medicine Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Editas Medicine Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Editas Medicine Inc Frequently Asked Questions
What is Editas Medicine Inc(EDIT)'s stock price today?
The current price of EDIT is $1.89. The 52 week high of EDIT is $11.58 and 52 week low is $1.89.
When is next earnings date of Editas Medicine Inc(EDIT)?
The next earnings date of Editas Medicine Inc(EDIT) is 2025-02-28 Est..
Does Editas Medicine Inc(EDIT) pay dividends? If so, how much?
Editas Medicine Inc(EDIT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers